SCYX

SCYNEXIS, Inc. (SCYX) - Q2 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2026. SCYNEXIS, Inc. is a clinical-stage biotechnology company focused on developing therapies for severe rare diseases and difficult-to-treat infections. The company's pipeline is led by SCY-770, a direct AMPK activator for Autosomal Dominant Polycystic Kidney Disease (ADPKD), and SCY-247, a next-generation antifungal. The company also holds licensing rights to BREXAFEMME (ibrexafungerp), which was licensed to GSK in 2023.

Key Financial Metrics

Note: Net income for the quarter was driven primarily by a non-cash gain on warrant liability fair value adjustments.

Material Changes vs. Prior Period

• Revenue Decline: License agreement revenue dropped 82.8% to $0.2 million for the quarter (from $1.4 million in Q2 2025) and 85.5% for the six-month period, reflecting the timing of payments under the GSK license agreement.
• Acquisition of SCY-770: In Q1 2026, the company acquired the SCY-770 program from Poxel SA for an upfront payment of $8.0 million, recognized as In-Process Research and Development (IPR&D) expense. This contributed to a 32.3% increase in R&D expenses for the six-month period compared to the prior year.
• Financing Activity: In March 2026, the company completed a private placement raising $40.0 million in gross proceeds ($36.9 million net). This significantly increased cash and investment balances compared to December 31, 2025.
• Reverse Stock Split: A 1-for-8 reverse stock split was effected on May 29, 2026, reducing outstanding shares from ~79.5 million to ~9.9 million to regain Nasdaq compliance.
• Warrant Liability Gain: The company recognized a $14.2 million gain in Q2 2026 (vs. $2.2 million in Q2 2025) due to the fair value adjustment of warrant liabilities, primarily driven by a decrease in the company's stock price and the reclassification of certain warrants to equity upon shareholder approval.

Guidance, Outlook, and Risks

• Development Timeline: Management anticipates completing a Phase 1 confirmatory study for SCY-770 in Q3 2026 and initiating a Phase 2 proof-of-concept study in Q4 2026. An early efficacy readout is expected in H2 2027.
• Liquidity Outlook: With $71.1 million in cash and investments as of June 30, 2026, management believes resources are sufficient to fund operations into 2029. Additional proceeds of up to $52.2 million could be realized if warrants from the March 2026 private placement are fully exercised.
• Risks: The company remains in a pre-revenue stage with an accumulated deficit of $399.0 million. Future funding requirements depend on clinical trial outcomes, regulatory approvals, and the ability to raise additional capital. The company faces risks related to the development of SCY-770 and SCY-247, including potential negative regulatory events or unanticipated costs.
• Unusual Items: The net income reported for the quarter is non-recurring and driven by accounting adjustments to warrant liabilities rather than operational performance. The company continues to incur significant operating losses.

Investor Verification Checklist

• Warrant Liability Accounting: Verify the impact of the $14.2 million non-cash gain on warrant liabilities on the reported net income and the remaining liability balance of $0.8 million.
• Cash Runway: Confirm the $71.1 million liquidity position and the assumptions regarding the 2029 funding horizon, particularly given the high burn rate.
• SCY-770 Milestones: Monitor the timeline for the Phase 1 confirmatory study (Q3 2026) and the Phase 2 initiation (Q4 2026) as critical value drivers.
• Private Placement Terms: Review the terms of the March 2026 private placement, specifically the exercise price of $9.60 for common warrants and the potential for dilution upon exercise.
• Revenue Recognition: Assess the sustainability of revenue streams, noting the significant decline in license revenue from GSK compared to the prior year.